Enhabit’s (EHAB) Market Perform Rating Reiterated at Leerink Partners

Enhabit (NYSE:EHAB)‘s stock had its “market perform” rating restated by research analysts at Leerink Partners in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $8.00 price objective on the stock, down from their prior price objective of $8.50. Leerink Partners’ target price points to a potential upside of 13.64% from the company’s previous close.

Enhabit Stock Performance

NYSE EHAB traded down $0.10 during trading on Tuesday, hitting $7.04. 23,093 shares of the company’s stock traded hands, compared to its average volume of 579,649. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The stock has a market capitalization of $353.97 million, a price-to-earnings ratio of -3.03 and a beta of 1.84. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74. The business has a 50 day moving average of $7.56 and a 200-day moving average of $8.47.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to analysts’ expectations of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the previous year, the company posted $0.03 earnings per share. As a group, equities research analysts anticipate that Enhabit will post 0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey Bolton purchased 5,000 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $8.01 per share, with a total value of $40,050.00. Following the acquisition, the director now directly owns 78,877 shares in the company, valued at approximately $631,804.77. This trade represents a 6.77 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enhabit

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC increased its stake in Enhabit by 138.4% in the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after acquiring an additional 1,967 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Enhabit in the second quarter worth approximately $31,000. Quarry LP raised its stake in Enhabit by 242.2% in the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after purchasing an additional 2,621 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Enhabit during the first quarter valued at approximately $44,000. Finally, Stoneridge Investment Partners LLC purchased a new stake in shares of Enhabit during the 3rd quarter valued at $81,000.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.